Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-Agonists.

Next Previous
Search
Trial Profile

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-Agonists.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms eXplore
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 20 Mar 2012 Planned number of patients changed from 67 to 96 as reported by European Clinical Trials Database.
    • 06 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Oct 2011 Planned end date changed from 1 Oct 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top